Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2015 Jun 23;24(9):1419–1422. doi: 10.1158/1055-9965.EPI-15-0541

Figures 1a–d. Hazard Ratios and 95% Confidence Intervals, Estrogen Metabolites and CRC (Parent Estrogens, 2-Pathway, 16-Pathway and 4-Pathway EM, figures 1a–d, respectively). Time scale for HR estimates is age at entry (baseline) through age at diagnosis or censoring (exit). For cases not in the subcohort, follow-up began 6 months prior to their CRC diagnosis. HR are adjusted for clinic, age at blood draw, bone mineral density, and trial participation.

Figures 1a–d. Hazard Ratios and 95% Confidence Intervals, Estrogen Metabolites and CRC (Parent Estrogens, 2-Pathway, 16-Pathway and 4-Pathway EM, figures 1a–d, respectively). Time scale for HR estimates is age at entry (baseline) through age at diagnosis or censoring (exit). For cases not in the subcohort, follow-up began 6 months prior to their CRC diagnosis. HR are adjusted for clinic, age at blood draw, bone mineral density, and trial participation.